Associations of B-Type Natriuretic Peptide and Its Coding Gene Promoter Methylation With Functional Outcome of Acute Ischemic Stroke: A Mediation Analysis.

Aili Wang,Mingzhi Zhang,Yi Ding,Xingbo Mo,Chongke Zhong,Zhengbao Zhu,Daoxia Guo,Xiaowei Zheng,Tan Xu,Yan Liu,Yonghong Zhang,Hao Peng
DOI: https://doi.org/10.1161/jaha.120.017499
IF: 6.106
2020-09-04
Journal of the American Heart Association
Abstract:Background The prognostic role of B‐type natriuretic peptide (BNP) in stroke has been suggested, but limited studies have shown mixed results and unknown underlying mechanisms. DNA methylation, a molecular modification that alters gene expression, may represent a candidate mechanism for this purpose. We aimed to examine the associations of BNP and methylation of its coding gene (natriuretic peptide B [ NPPB ]) with the functional outcome in a large sample of patients with acute ischemic stroke from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). Methods and Results Leveraging participants from CATIS with available specimens, serum proBNP (equimolarly produced with BNP) was measured in 3216 patients (mean age, 62 years; 64% men), and peripheral blood DNA methylation of the NPPB promoter was quantified by targeted bisulfite sequencing in 806 patients (mean age, 62 years; 54% men). The functional outcome was defined as an ordered modified Rankin Scale score assessed at 14 days or hospital discharge after stroke onset. Mediation analysis was conducted to test the potential mediating effect of proBNP on the relationship between NPPB methylation and functional outcome. The results showed that a higher level of proBNP was significantly associated with a higher risk of having a poorer functional outcome (odds ratio [OR], 1.14; P =0.006). Every 5% of hypermethylation at 2 (Chr1:11919160 [OR, 0.93; P =0.022] and Chr1:11918989 [OR, 0.92; P =0.032]) of 11 CpG loci assayed was associated with 7% and 8% lower risk, respectively, of having a poor functional outcome. In addition, proBNP was negatively correlated to hypermethylation at 1 CpG (Chr1:11918989 [β=−0.029; P =0.009]) and mediated approximately 7.69% (95% CI, 2.50%–13.82%) of the association between this CpG methylation and the functional outcome. Conclusions Hypermethylation at the NPPB promoter is associated with the functional outcome after ischemic stroke, at least partially by suppressing BNP expression or excretion. Nonstandard Abbreviations and Acronyms AIS acute ischemic stroke BNP B‐type natriuretic peptide CATIS China Antihypertensive Trial in Acute Ischemic Stroke KEGG Kyoto Encyclopedia of Genes and Genomes mRS modified Rankin Scale NIHSS National Institutes of Health Stroke Scale NPPB natriuretic peptide B Clinical Perspective What Is New? Hypermethylation at the natriuretic peptide B ( NPPB ) promoter is associated with functional outcome after ischemic stroke. Hypermethylation at the NPPB promoter is associated with lower circulating levels of pro–B‐type natriuretic peptide. What Are the Clinical Implications? Hypermethylation at the NPPB promoter may be a marker of poor functional outcome after ischemic stroke. Hypermethylation at the NPPB promoter may be potential drug target for ischemic stroke. B‐type natriuretic peptide (BNP) is a circulating cardiac hormone synthesized and released as a precursor protein, mainly from the ventricles, in response to increased myocardial wall stress related to volume or pressure overload. 1 It has been globally endorsed in clinical guidelines as a biomarker to aid in the diagnosis of heart failure and to monitor disease progression. 2 , 3 , 4 In addition to heart diseases, BNP was elevated in patients with acute ischemic stroke (AIS) 5 , 6 and associated with the poor functional outcome of AIS, 7 , 8 , <a class= -Abstract Truncated-
cardiac & cardiovascular systems
What problem does this paper attempt to address?
The aim of this paper is to explore the relationship between B-type natriuretic peptide (BNP) and the methylation of its encoding gene (NPPB) promoter with the functional prognosis of patients with acute ischemic stroke. Specifically, the objective of the study is to investigate whether BNP levels and the methylation status of the NPPB gene promoter region can predict the functional outcomes of acute ischemic stroke in a large sample from the China Antihypertensive Acute Ischemic Stroke Trial (CATIS), and to further analyze whether BNP mediates the relationship between NPPB gene promoter methylation and functional outcomes. The study found that higher methylation of the NPPB gene promoter is associated with better functional recovery, and this association is partially mediated by the influence on BNP concentration. This suggests that NPPB gene methylation may be involved in the molecular mechanisms linking BNP to the functional prognosis of acute ischemic stroke.